Your browser doesn't support javascript.
loading
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley, John F; Defer, Gilles; Ryerson, Lana Zhovtis; Cohen, Jeffrey A; Arnold, Douglas L; Butzkueven, Helmut; Cutter, Gary; Giovannoni, Gavin; Killestein, Joep; Wiendl, Heinz; Smirnakis, Karen; Xiao, Shan; Kong, George; Kuhelj, Robert; Campbell, Nolan.
Affiliation
  • Foley JF; Rocky Mountain MS Clinic, Salt Lake City, UT, USA. Electronic address: jfoley@rmmsc.com.
  • Defer G; Department of Neurology, Centre Hospitalier Universitaire de Caen, Caen, France.
  • Ryerson LZ; NYU Multiple Sclerosis Center, NYU Langone Health, New York, NY, USA.
  • Cohen JA; Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Arnold DL; Montreal Neurological Institute, McGill University, Montréal, QC, Canada; NeuroRx Research, Montréal, QC, Canada.
  • Butzkueven H; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.
  • Cutter G; University of Alabama at Birmingham, School of Public Health, Birmingham, AL, USA.
  • Giovannoni G; Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK; Queen Mary University of London, London, UK.
  • Killestein J; Department of Neurology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Netherlands.
  • Wiendl H; Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany.
  • Smirnakis K; Biogen, Cambridge, MA, USA.
  • Xiao S; Biogen, Cambridge, MA, USA.
  • Kong G; Biogen, Cambridge, MA, USA.
  • Kuhelj R; Biogen, Baar, Switzerland.
  • Campbell N; Biogen, Cambridge, MA, USA.
Lancet Neurol ; 21(7): 608-619, 2022 07.
Article in En | MEDLINE | ID: mdl-35483387
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukoencephalopathy, Progressive Multifocal / Multiple Sclerosis, Relapsing-Remitting / Multiple Sclerosis Type of study: Clinical_trials / Risk_factors_studies Limits: Humans Language: En Journal: Lancet Neurol Journal subject: NEUROLOGIA Year: 2022 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukoencephalopathy, Progressive Multifocal / Multiple Sclerosis, Relapsing-Remitting / Multiple Sclerosis Type of study: Clinical_trials / Risk_factors_studies Limits: Humans Language: En Journal: Lancet Neurol Journal subject: NEUROLOGIA Year: 2022 Document type: Article Country of publication: